146 related articles for article (PubMed ID: 7487127)
1. [A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin].
Tsukuda M; Mochimatsu I; Furukawa M; Kohno H; Kawai S; Enomoto H; Yago T; Matsuda H; Ikema Y; Zhou L
Gan To Kagaku Ryoho; 1995 Nov; 22(13):1959-67. PubMed ID: 7487127
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin.
Hashizume J; Higuchi N; Sato K; Kodama Y; Matsunaga N; Sakamoto T; Yamaguchi K; Nakamura T; Kitahara T; Sasaki H
Biol Pharm Bull; 2016; 39(4):611-4. PubMed ID: 27040634
[TBL] [Abstract][Full Text] [Related]
3. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
4. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Massidda B; Ionta MT
J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
[TBL] [Abstract][Full Text] [Related]
5. [Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy].
Okuyama K; Yoshimoto K; Iwase O; Ozeki T; Yamada Y
Yakugaku Zasshi; 2008 Apr; 128(4):649-55. PubMed ID: 18379183
[TBL] [Abstract][Full Text] [Related]
6. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intravenous granisetron with metoclopramide in the treatment of chemotherapy-induced emesis.
Chiou TJ; Wei CH; Hsieh RK; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jul; 56(1):23-30. PubMed ID: 7553406
[TBL] [Abstract][Full Text] [Related]
8. [A randomized crossover comparison of azasetron alone and azasetron plus dexamethasone for the prevention of nausea and vomiting by chemotherapy including cisplatin].
Fujii M; Kanke M; Arai Y; Kawai S; Enomoto H; Inaba H; Taguchi T; Tsukuda M
Gan To Kagaku Ryoho; 2000 Sep; 27(10):1557-63. PubMed ID: 11016001
[TBL] [Abstract][Full Text] [Related]
9. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
10. [Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers].
Ishioka S; Sagae S; Saito T; Kiya T; Sugimura M; Akutagawa N; Umemura K; Ito E; Kudo R
Gan To Kagaku Ryoho; 2000 Apr; 27(4):593-8. PubMed ID: 10791002
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients].
Hayakawa T; Sato M; Konaka M; Makino A; Hirohata T; Totsu S; Wada Y; Sato H; Inotsume N; Fujita A; Sekine K
Gan To Kagaku Ryoho; 2006 May; 33(5):633-8. PubMed ID: 16685162
[TBL] [Abstract][Full Text] [Related]
12. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group.
Ruff P; Paska W; Goedhals L; Pouillart P; Rivière A; Vorobiof D; Bloch B; Jones A; Martin C; Brunet R
Oncology; 1994; 51(1):113-8. PubMed ID: 8265095
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
[TBL] [Abstract][Full Text] [Related]
14. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
Navari RM; Reinhardt RR; Gralla RJ; Kris MG; Hesketh PJ; Khojasteh A; Kindler H; Grote TH; Pendergrass K; Grunberg SM; Carides AD; Gertz BJ
N Engl J Med; 1999 Jan; 340(3):190-5. PubMed ID: 9917226
[TBL] [Abstract][Full Text] [Related]
15. Clinical comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea and anorexia.
Feng F; Zhang P; He Y; Li Y; Zhou M; Chen G; Li L
Chin Med Sci J; 2002 Sep; 17(3):168-72. PubMed ID: 12901541
[TBL] [Abstract][Full Text] [Related]
16. Comparison of granisetron alone and granisetron plus hydroxyzine hydrochloride for prophylactic treatment of emesis induced by cisplatin chemotherapy.
Tsukuda M; Furukawa S; Kokatsu T; Enomoto H; Kubota A; Furukawa M
Eur J Cancer; 1995 Sep; 31A(10):1647-9. PubMed ID: 7488417
[TBL] [Abstract][Full Text] [Related]
17. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.
Latreille J; Pater J; Johnston D; Laberge F; Stewart D; Rusthoven J; Hoskins P; Findlay B; McMurtrie E; Yelle L; Williams C; Walde D; Ernst S; Dhaliwal H; Warr D; Shepherd F; Mee D; Nishimura L; Osoba D; Zee B
J Clin Oncol; 1998 Mar; 16(3):1174-8. PubMed ID: 9508205
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy.
Latreille J; Stewart D; Laberge F; Hoskins P; Rusthoven J; McMurtrie E; Warr D; Yelle L; Walde D; Shepherd F
Support Care Cancer; 1995 Sep; 3(5):307-12. PubMed ID: 8520877
[TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of Azasetron Hydrochloride: a new selective 5-HT3 receptor antagonist--antiemetic profile and plasma concentration in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma].
Beppu T; Ogawa M; Yamanaka T; Egami H; Ohara C; Masuda Y; Kudo S; Kuramoto M; Doi K; Matsuda T
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1197-202. PubMed ID: 9679583
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer].
Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M; Kanzaki J
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1095-101. PubMed ID: 9239162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
